COR2ED - Oncology Medical Conversation

Dr Neal Shore, Uro-Oncologist and Chief Medical Officer for Genesis Care and Urology and Surgical Oncology in the United States and Dr Elena Castro, Medical Oncologist at Hospital Universitario 12 de Octubre in Madrid, discuss clinical implementation of PARP inhibitor monotherapy for prostate cancer patients, providing both a US and EU perspective. In this podcast, the experts discuss the key effi...

Join world-renowned gynaecological oncology experts Dr Domenica “Ketta” Lorusso and Dr Mansoor Mirza as they explore the changing landscape of systemic treatment in endometrial carcinoma. Single-agent immunotherapies (pembrolizumab and dostarlimab), and now immunotherapy and antiangiogenic therapy combinations (pembrolizumab and lenvatinib), are transforming treatment pathways, with OS benefits in...

This episode, covers the highlights on colorectal cancer from ASCO GI 2023.  Prof. Andrea Sartore-Bianchi (Niguada Cancer Center, Milan, Italy) and Prof. Shubham Pant (MD Anderson Cancer Center, Houston, TX, USA) discuss a number of key abstracts from the meeting and their implications for clinical practice. The experts start by discussing the SUNLIGHT trial which studied the use of trifluridine/t...

This episode, covers the highlights on gastroesophageal, gastric and gastroesophageal junction (GEJ) cancer from ASCO GI 2023.  Dr Nataliya Uboha (University of Wisconsin, USA) and Dr Efrat Dotan(Fox Chase Cancer Center, USA) discuss a number of key abstracts from the meeting and their implications for clinical practice.  The experts start by covering a number of metastatic studies.  First of all,...

In this podcast, Prof. Jonathan Trent and Prof. Robin Jones discuss what’s new in the patient management in sarcoma from CTOS 2022. The Connective Tissue Oncology Society is an international group of physicians and scientists with a primary interest in the tumours of connective tissues. With nearly 600 attendees, 10 sessions specific for sarcoma, and over 300 posters, CTOS 2022 took place between...

Prof. Thomas Powles, a Medical Oncologist from Barts Cancer Centre in the UK and Dr Friederike Schlürmann a Medical Oncologist from University Hospital of Brest and Quimper in France, discuss the clinical implementation of targeted and immunotherapies for advanced renal cell carcinoma (RCC). In this podcast, the two experts discuss data from key trials CHECKMATE 214 (ipilimumab and nivolumab), KEY...

In this podcast, Prof. Martyn Caplin and Dr Aman Chauhan discuss the role of somatostatin analogues (SSAs) at progression and whether to continue or not. In patients with well-differentiated Grade 1/2 neuroendocrine tumours (NETs) and slowly progressive asymptomatic disease, potential strategies for continuing SSA at progression include increasing the SSA dose frequency from every four to every tw...

In this HCC CONNECT podcast HCC Experts Prof. Matthias Pinter and Prof. Jeroen Dekervel, discuss and debate the clinical implications of new HCC Phase 3 clinical trials data presented and discussed at the ILCA and ESMO congresses. They discuss Immuno-oncology agents and their place in the upcoming updated guidance such as the proposed new ILCA Systemic Therapies Guidance algorithm. They also discu...

This second GI CONNECT podcast episode, covers the highlights on gastroesophageal cancer from ESMO 2022.   Dr Sam Klempner (Massachusetts General Hospital, Boston, USA) and Dr Yelena Janjigian (Memorial Sloan Kettering Cancer Center, New York, USA) discuss a number of key posters and oral presentations from the meeting and their implications for clinical practice. The experts start by covering a n...

In the first episode of this GI CONNECT podcast covering the lower gastrointestinal (GI) cancer highlights from ESMO 2022, Dr Jenny Seligmann, Medical Oncologist from the University of Leeds in the UK and Dr Dominik Modest, Medical Oncologist from the Charité Universitaetsmedizin, Berlin, Germany discuss a number of key oral presentations from ESMO 2022 and potential implications for clinical prac...

In this podcast, Sven De Keersmaecker, RN and Assoc. Prof. Gerald Prager, MD discuss flexible dosing regimens of the oral treatments regorafenib, trifluridine / tipiracil (TAS-102) and capecitabine to optimise treatment duration and to manage adverse events in patients with metastatic colorectal cancer.   The two experts also discuss the importance of keeping patients on treatment to optimise outc...

In this SARCOMA CONNECT Guidelines Podcast, two SARCOMA CONNECT Experts, Prof. Robert Maki and Prof. Silvia Stacchiotti, discuss recent updates in the ESMO and NCCN bone sarcoma guidelines . Focussing on  osteosarcoma and Ewing sarcoma , but also including chordoma and Giant Cell Tumour of bone , the Experts compare and contrast the latest updates to the guidelines. They highlight the key clinical...

In this podcast, liver cancer experts Prof. Amit Singal and Assoc. Prof Neil Mehta discuss recent advances in systemic and locoregional therapy for advanced and early stage hepatocellular carcinoma (HCC).   They focus on the role of immunotherapy and review data from three major congresses in 2022 (ASCO, WCGIC and ILC) together with recent publications.   Prof. Amit Singal is Director of Liver Can...

In this podcast Dr Jason Alcorn and Jennifer Sutton discuss the oncology nursing highlights from ASCO GU, ASCO and EAUN 2022.  The experts discuss: Treatment intensification with triplet therapy for mCSPC patients with practice changing data from the ARASENS trial and updated overall survival from the ENZAMET trial Subgroup analysis of prior and concomitant treatment from the VISION trial A number...

Brenda Martone , a nurse practitioner at Northwestern Medicine in Chicago Illinois and Dr Alicia Morgans , Genitourinary Medical Oncologist at the Dana-Farber Cancer Institute in the United States discuss ‘Shared decision-making in nmCRPC: Treatment considerations to maintain quality of life’ in this GU CONNECT podcast. In this podcast, the experts discuss how patients are more likely to be able t...

Dr. Tanya Dorff, a Medical Oncologist from the City of Hope Comprehensive Cancer Center and Dr. Neal Shore, Uro-Oncologist and Chief Medical Officer for Genesis Care and Urology and Surgical Oncology in the United States discuss ‘Timing of ARSI and taxanes for mCSPC’ in this GU CONNECT podcast. In this podcast, the experts reflect on how the treatment landscape for mCSPC has evolved over the past...

In this podcast, Beth Wittmer RN, Director of Care Management at Florida Cancer Specialists, USA and Prof. Hans Prenen, GI Medical Oncologist from Antwerp University Hospital, Belgium, discuss the management of dermatological side effects that patients may experience when receiving treatment with multikinase inhibitors , such as regorafenib , sunitinib , cabozantinib amongst others.   They discuss...

In this podcast episode, myeloma experts Dr. María Victoria Mateos (Haematologist at the University Hospital Salamanca, Spain) and Dr. Alexander Lesokhin (Associate Attending on the Myeloma Service at the Memorial Sloan Kettering Cancer Center, New York, NY, USA) discuss how they choose the best treatment regimen for patients with multiple myeloma and a high-risk cytogenetic profile.   Firstly, th...

COR2ED Medical Education: Dr Alicia Morgans, Genitourinary Medical Oncologist at the Dana-Farber Cancer Institute in the United States and Dr. Neal Shore, Uro-Oncologist and Chief Medical Officer for Genesis Care and Urology and Surgical Oncology in the United States discuss ‘Prostate Cancer Highlights from ASCO GU 2022’ in this GU CONNECT podcast. In this podcast, the experts review data from a n...

Medical Education podcast by COR2ED. Professor James Harding, HCC Connect member, provides his perspectives and insights on key abstracts and topics discussed at ASCO GI 2022 and EASL liver cancer summit 2022 in hepatocellular carcinoma. He discusses the HIMALAYA study which evaluated dual immune checkpoint blockade inhibition namely, anti-CTLA-4 antibody tremelimumab with the anti-PD-L1 antibody...

COR2ED Medical Education: Dr Jason Alcorn, nurse consultant for Uro-Oncology & Andrology at the Mid Yorkshire Hospitals NHS Trust, United Kingdom and Dr Alicia Morgans, Genitourinary Medical Oncologist and Medical Director of the Survivorship Program at the Dana-Farber Cancer Institute in the United States, discuss ' PARP inhibitors in prostate cancer: Management of adverse events and the impo...

COR2ED Educación Médica: Pablo Peinado, coordinador de Enfermería de Investigación, y la Dra. Elena Castro, oncóloga médica, quienes trabajan en el Hospital Universitario Virgen de la Victoria de Málaga en España, discuten 'El potencial de los inhibidores de PARP en el cáncer de próstata: Lo que las enfermeras necesitan para saber'. En este podcast, los expertos analizan los inhibidores de PARP (P...

COR2ED Medical Education: Pablo Peinado, Research Nurse Coordinator, and Dr. Elena Castro, medical oncologist, who both work at Hospital Universitario Virgen de la Victoria in Malaga in Spain, discuss ‘The potential of PARP inhibitors in prostate cancer: What nurses need to know’.   In this podcast, the experts discuss PARP inhibitors (PARPi’s), how they work and key data from the registration tri...

COR2ED Medical Education: Joanne Chien, Nurse Practitioner specialising in urologic cancers at Stanford Health Care in Palo Alto, California, and Dr Alexander Wyatt, Assistant Professor in genitourinary cancer genomics at the Vancouver Prostate Centre, Department of Urologic Sciences at the University of British Columbia, discuss ‘ Genetic testing and PARP inhibitors in prostate cancer ’ as part o...

In this medical education podcast, NTRK CONNECT members Assoc. Prof. Caterina Marchiò (University of Turin, Italy) and Prof. Christian Rolfo (Center of Thoracic Oncology Tisch Cancer Institute Icahn School of Medicine at Mount Sinai, New York, USA) provide pathologist and medical oncologist perspectives about the detection and treatment of TRK fusion-positive lung cancers. They discuss a number of...